UFP Technologies Sees Surge in Revenue and Market Cap

By Tamara Parker • Friday, August 22 13:21 • Permanent Link

UFP Technologies, a contract development and manufacturing organization (CDMO) specializing in single-use polymer-based medical devices, has seen significant growth in its financial metrics since August 2022. Here are some key figures to note:

Annual Revenue: UFP Technologies has seen a substantial increase in its annual revenue, with the latest figure standing at approximately $600 million as of August 2025, compared to the previous figure of $451 million in 2023.
Market Cap: The company's market capitalization has also experienced significant growth, reaching approximately $1.95 billion as of August 2025.
MedTech Sales: The company's focus on the MedTech segment has been fruitful, with MedTech sales showing a steady increase over time, reaching approximately $540 million in the latest twelve-month period ended June 30, 2025, compared to $132 million in 2021.
Financial Targets: UFP Technologies has set ambitious financial targets for the next 3 to 5 years, aiming for 12-18% revenue growth, 28-31% gross margin, and 17-20% adjusted operating margin.
Gross Margin: The company has made progress in improving its gross margin, with the target range set at 28-31%. The latest figures show a substantial increase, with the gross margin reaching 29.1% in the second quarter year to date, compared to 24.8% in 2021.
Adjusted Operating Margin: UFP Technologies has also shown improvement in its adjusted operating margin, with the target range set at 17-20%. The latest figures indicate an adjusted operating margin of 17.7% in the second quarter year to date, compared to 11.1% in 2021.

Today the company's shares have moved 0.08% to a price of $219.56. For the full picture, make sure to review UFP TECHNOLOGIES INC's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.